| 1 |
中国临床肿瘤学会血管靶向治疗专家委员会，中国临床肿瘤学会非小细胞肺癌专家委员会，中国临床肿瘤学会非小细胞肺癌抗血管生成药物治疗专家组．晚期非小细胞肺癌抗血管生成药物治疗中国专家共识(2020版)[J]. 中华肿瘤杂志，2020, 42(12): 1063-1077.
|
| 2 |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| 3 |
Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening[J]. N Engl J Med, 2006, 355: 1763-1771.
|
| 4 |
Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019[J]. CA Cancer J Clin, 2019, 69(5): 363-385.
|
| 5 |
Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review[J]. JAMA, 2012, 307: 2418-2429.
|
| 6 |
Walter JE, Heuvelmans MA, Oudkerk M, et al. Small pulmonary nodules in baseline and incidence screening rounds of low-dose CT lung cancer screening[J]. Transl Lung Cancer Res, 2017, 6(1): 42-51.
|
| 7 |
Oudkerk M, Liu S, Heuvelmans MA, et al. Lung cancer LDCT screening andmortality reduction-evidence, pitfalls and future perspectives [J]. Nat Rev ClinOncol, 2021, 18(3): 135-151.
|
| 8 |
朱梦婵，邰先桃，王 坚，等. 外泌体及外泌体微小RNA在肺动脉高压中的作用与机制[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(6): 776-779.
|
| 9 |
Sozzi G, Boeri M, Rossi M, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study[J]. J Clin Oncol, 2014, 32(8): 768-773.
|
| 10 |
Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution[J]. Nature, 2017, 545(7655): 446-451.
|
| 11 |
Hodgkinson CL, Morrow CJ, Li Y, et al. Tumorigenicity and genetic profiling of circulating tumor cells in smallcell lung cancer[J]. Nat Med, 2014, 20(8): 897- 903.
|
| 12 |
Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis[J]. J ClinInvest, 2001, 108(10): 1411-1415.
|
| 13 |
Tan EM, Koziol JA. Autoantibodies in prostate cancer [J]. N Engl J Med, 2005, 353(26): 2815-2817.
|
| 14 |
Kobayashi M, Katayama H, Fahrmann JF, et al. Development of autoantibody signatures for common cancers [J]. Semin Immunol, 2020, 47: 101388.
|
| 15 |
Kolkhir P, Metz M, Altrichter S, et al. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review [J]. Allergy, 2017, 72(10): 1440-1460.
|
| 16 |
Damato V, Balint B, Kienzler AK, et al. The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders [J]. Mov Disord, 2018, 33(9): 1376-1389.
|
| 17 |
Chapman CJ, Murray A, McElveen JE, et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure[J]. Thorax, 2008, 63(3): 228- 233.
|
| 18 |
Desmetz C, Mange A, Maudelonde T, et al. Autoantibody signatures：progressand perspectives for early cancer detection[J]. J Cell Mol Med, 2011, 15(10): 2013-2024.
|
| 19 |
Chen HD, Werner S, Tao S, et al. Blood autoantibodies against tumor-associatedantigens as biomarkers in early detection of colorectal cancer[J]. Cancer Lett, 2014, 346(2): 178-187.
|
| 20 |
Murray A, Chapman CJ, Healey G, et al. Technical validation of an autoantibody test for lung cancer[J]. Ann Oncol, 2010, 21(8): 1687-1693.
|
| 21 |
Chapman C, Murray A, Chakrabarti J, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis[J]. Ann Oncol, 2007, 18(5): 868-873.
|
| 22 |
Wu L, Chang W, Zhao J, et al. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer[J]. Clin Cancer Res, 2010, 16(14): 3760-3768.
|
| 23 |
Dail LP, Tsay JC, Li J, et al. Autoantibodies against tumor-associated antigens in the early detection of lung cancer[J]. Lung Cancer, 2016, 99: 172-179.
|
| 24 |
Boyle P, Chapman C, Holdenrieder S, et al. Clinical validation of an autoantibody test for lung cancer[J]. Ann Oncol, 2011, 22(2): 383-389.
|
| 25 |
Sullivan FM, Mair FS, Anderson W, et al. Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging[J]. Eur Respir J, 2021, 57(1): 2000670.
|
| 26 |
Ren S, Zhang S, Jiang T, et al. Early detection of lung cancer by using an autoantibody panel in Chinese population[J]. Oncoimmunology, 2017, 7(2): 1384108.
|
| 27 |
Sullivan FM, Farmer E, Mair FS, et al. Detection in blood of autoantibodies totumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial[J]. BMC Cancer, 2017, 17(1): 187.
|
| 28 |
Meyer N, Penn LZ. Reflecting on 25 years with MYC[J]. Nat Rev Cancer, 2008, 8(12): 976-990.
|
| 29 |
Panda S, Banerjee N, Chatterjee S. Solute carrier proteins and c-Myc: A strong connection incancer progression[J]. Drug Discov Today, 2020, 25(5): 891-900.
|
| 30 |
Elbadawy M, Usui T, Yamawaki H, et al. Emerging roles of C-Myc in cancer stem cell related signaling and resistance to cancer chemotherapy: A potential therapeutic target against colorectal cancer[J]. Int J Mol Sci, 2019, 20(9): 2340.
|
| 31 |
Li P, Shi JX, Dai LP, et al. Serum anti-MDM2 andanti-c-Myc autoantibodies as biomarkers in the early detection of lung cancer[J]. Oncoimmunology, 2016, 5(5): 1138200.
|
| 32 |
Duan Y, Cui C, Qiu C, et al. Serum Autoantibodies against LRDD, STC1, and FOXA1 as Biomarkers in the Detection of Ovarian Cancer[J]. Dis Markers, 2022, 2022: 6657820.
|
| 33 |
Zhang X, Li J, Wang Y, et al. A Diagnostic Model With IgM Autoantibodies and Carcinoembryonic Antigen for Early Detection of Lung Adenocarcinoma[J]. Front Immunol, 2022, 12: 728853.
|
| 34 |
Li S, Ma Y, Xiong Y, et al. Five tumor-associated autoantibodies expression levels in serum predict lung cancer and associate with poor outcome[J]. Transl Cancer Res, 2019 , 8(4): 1364-1373.
|